Early studies have shown that blocking FZDs could inhibit angiogenesis and tumor growth [19], and application of the purified extracellular domain of FZD7 could decrease β-catenin/TCF4 transcriptional activity [20]. The gene discussed is FZD7; the disease is neoplasm.